These data are especially pivotal in the current panorama in which identification of several well-known and other less explored genetic aberrations are essential for therapeutic stratification, as tools in patient clinical guidance and as potential treatment targets (typical SCA, ALK mutation, ALT alterations). This evidence concerns the gene GPT and autosomal dominant cerebellar ataxia.